Journals / Nöropsikiyatri Arşivi / 2021 / Cilt: 58 - Sayı: 2

Atypical Neuroleptic Malignant Syndrome Induced by Low Dose Quetiapine in a Patient Treated with Donepezil

Donepezil Kullanan Bir Hastada Düşük Doz Ketiyapine Bağlı Olarak Gelişen Atipik Nöroleptik Malign Sendrom

Pages
166–168
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this report, we aim to present a case with atypical neuroleptic malignant syndrome associated with the use of very low dose quetiapine and discuss the risk factors that facilitate its emergence.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neuroleptic malignant syndrome is a rare idiosyncratic drug reaction that causes morbidity and mortality.
📊
Key Findings & Data:Although muscle rigidity and fever are accepted as major symptoms, there is no consensus on the diagnostic criteria.
💡
Conclusion & Impact:In this report, we aim to present a case with atypical neuroleptic malignant syndrome associated with the use of very low dose quetiapine and discuss the risk factors that facilitate its emergence.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Neuroleptic malignant syndrome is a rare idiosyncratic drug reaction that causes morbidity and mortality. Although muscle rigidity and fever are accepted as major symptoms, there is no consensus on the diagnostic criteria. This flexibility in diagnostic criteria allows for the diagnosis of atypical cases. Keeping in mind that neuroleptic malignant syndrome may also occur with the use of low doses of atypical antipsychotics is important for making the diagnosis quickly and reducing the risk of morbidity and mortality. In this report, we aim to present a case with atypical neuroleptic malignant syndrome associated with the use of very low dose quetiapine and discuss the risk factors that facilitate its emergence.

Özet

Nöroleptik malign sendrom nadir görülen ancak hastalık ve ölümeneden olan bir idiyosenkratik ilaç tepkisidir. Kaslarda katılık ve ateşana belirtiler olarak kabul edilmekle birlikte tanı ölçütlerinde fikirbirliği bulunmamaktadır. Tanı ölçütlerindeki esneklik atipik vakalarıntanınmasına olanak sağlamaktadır. Atipik antipsikotiklerin düşükdozlarının kullanımıyla nöroleptik malign sendrom gelişebileceğininakılda tutulması; hızlı bir şekilde tanı konulması, hastalık ve ölüm riskininazalması bakımından önemlidir. Bu vakada düşük dozda ketiyapinkullanımı ile ortaya çıkan atipik nöroleptik malign sendrom tablosununve ortaya çıkışını kolaylaştıran risk faktörlerinin tartışılması amaçlanmıştır.

🔖

Cite This Article

EROĞLU, E. Ö., YILDIZ, İ., YAZICI, M. K. Z. (2021). Atypical Neuroleptic Malignant Syndrome Induced by Low Dose Quetiapine in a Patient Treated with Donepezil. Nöropsikiyatri Arşivi, Cilt: 58 - Sayı: 2, 166–168. https://ajindex.com/articles/340780

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009
  2. 477–492. [CrossRef] 2. Gurrera RJ, Caroff SN, Cohen A, Carroll BT, DeRoos F, Francis A, Frucht S, Gupta S, Levenson JL, Mahmood A, Mann SC, Policastro MA, Rosebush PI, Rosenberg H, Sachdev PS, Trollor JN, Velamoor VR, Watson CB, Wilkinson JR. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 2011
  3. 1222– 1228. [CrossRef] 3. Velamoor, R. Neuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management. Asian J Psychiatr 2017
  4. 106–109. [CrossRef] 4. Schneider M, Regente J, Greiner T, Lensky S, Bleich S, Toto S, Grohmann R, Stübner S, Heinze M. Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993–2015. Eur Arch Psychiatry Clin Neurosci 2020
  5. 23–33. [CrossRef] 5. Delay J, Pichot P, Lempiere T, Elissalde B, Peigne F. A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann Med Psychol (Paris) 1960
  6. 145–152. https://pubmed.ncbi.nlm.nih. gov/13815606/ 6. Gortney JS, Fagan A, Kissack JC. Neuroleptic malignant syndrome secondary to quetiapine. Ann Pharmacother 2009
  7. 785–791. [CrossRef] 7. Detweiler MB, Sullivan K, Sharma TR, Kim KY, Detweiler JG. Case reports of neuroleptic malignant syndrome in context of quetiapine use. Psychiatr Q 2013
  8. 523–541. [CrossRef] 8. Singhai K, Kuppili PP, Nebhinani N. Atypical neuroleptic malignant syndrome: A systematic review of case reports. Gen Hosp Psychiatry 2019
  9. 12–19. [CrossRef] 9. Sachdev P, Kruk J, Kneebone M, Kissane D. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol 1995
  10. 365–371. [CrossRef] 10. Almeida F, Albuquerque E, Murta I. Delirium Induced by Quetiapine and the Potential Role of Norquetiapine. Front Neurosci 2019
  11. 886–889. [CrossRef] 11. Belvederi Murri M, Guaglianone A, Bugliani M, Calcagno P, Respino M, Serafini G, Innamorati M, Pompili M, Amore M. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs RD 2015
  12. 45–62. [CrossRef] 12. El-Gaaly S, St John P, Dunsmore S, Bolton JM. Atypical neuroleptic malignant syndrome with quetiapine: a case report and review of the literature. J Clin Psychopharmacol 2009
  13. 497–499. [CrossRef] 13. Matsumoto